• 1
    Frolick C, Cain RL, Sato M, Harvey AK, Chandrasekhar S, Black EC, Tashjian AH Jr, Hock J 1999 Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analogue of human PTH-related protein (1-34): In vitro activity and in vivo pharmacological effects in rats. J Bone Miner Res 14: 163172
  • 2
    Vickery BH, Avnur Z, Cheng Y, Chiou S-S, Leaffer D, Caulfield JP, Kimmel DB, Ho T, Krstenansky JL 1996 RS-66271, a C-terminally substituted analogue of human parathyroid hormone-related protein (1-34), increases trabercular and cortical bone in ovariectomized, osteopenic rats. J Bone Miner Res 11: 19431951.
  • 3
    Goltzman D 1999 Interactions of PTH and PTHrP with the PTH/PTHrP receptor and with downstream signaling pathways: Exceptions that provide the rules. J Bone Miner Res 14: 173177.
  • 4
    Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF 1997 Conformational studies of RS-66271, an analogue of parathyroid hormone-related protein with pronounced bone anabolic activity. J Med Chem 40: 30253031.
  • 5
    Hoare SRJ, De Vries G, Usdin TB 1999 Measurement of agonist and antagonist ligand-binding parameters at the human parathyroid hormone type 1 receptor: Evaluation of receptor states and modulation by guanine nucleotide. J Pharm Exp Ther 289: 13231333.
  • 6
    Hoare SRJ, Usdin TB 1999 Quantitative cell membrane-basedradioligand binding assays for parathyroid hormone receptors. J Pharm Toxicol Methods 41: 8390.
  • 7
    Deléan A, Stadel JM, Lefkowitz RJ 1980 A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255: 71087117.
  • 8
    Friessmuth M, Waldhoer M, Bofill-Cardona E, Nanoff C 1999 G protein antagonists. Trends Pharmacol Sci 20: 237245.